PVH
58
5
CNP
59
17
DHI
36
3
HSIC
42
2
PHM
44
4
SO
48
6
MCD
52
3
LMT
29
-5
XRX
48
2
CI
35
2
BEN
36
4
ZTS
38
4
GME
61
2
IR
46
3
QRVO
16
-6
EFX
43
3
EW
55
5
DGX
28
4
STZ
42
2
UA
48
6
PVH
58
5
CNP
59
17
DHI
36
3
HSIC
42
2
PHM
44
4
SO
48
6
MCD
52
3
LMT
29
-5
XRX
48
2
CI
35
2
BEN
36
4
ZTS
38
4
GME
61
2
IR
46
3
QRVO
16
-6
EFX
43
3
EW
55
5
DGX
28
4
STZ
42
2
UA
48
6
Financhill
Back

Voyager Therapeutics 10K Form

Sell
19

VYGR
Voyager Therapeutics

Last Price:
$5.76
Seasonality Move:
19.91%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive VYGR News And Ratings

See the #1 stock for the next 7 days that we like better than VYGR

VYGR Financial Statistics

Sales & Book Value

Annual Sales: $250M
Cash Flow: $-28.2M
Price / Cash Flow: 44.4
Annual Sales: $6.06
Price / Book: 0.95

Profitability

EPS (TTM): 0.65000
Net Income (TTM): $25.9M
Gross Margin: --
Return on Equity: 9.12%
Return on Assets: 6.54%

Voyager Therapeutics Earnings Forecast

Key Voyager Therapeutics Financial Ratios

  • The Research & Development expenses have been 36.87% of Revenue.
  • The Net Earning history of VYGR is 52.93% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 5 years.

Voyager Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: VYGR
CUSIP: 92915B
Website: voyagertherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 8.45
Quick Ratio: 8.26

Price-to-Earnings

Trailing P/E Ratio: 1.94
Forward P/E Ratio: 0

VYGR Technical Analysis vs Fundamental Analysis

Sell
19
Voyager Therapeutics (VYGR) is a Sell

Is Voyager Therapeutics a Buy or a Sell?